- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04315740
Acute Health Effects Due to Ultrafine Particles From Candles and Cooking (Ultrafine)
THE ULTRAFINE PROJECT - A Study of Acute Health Effects of Exposure to Particles Generated by Candles and Cooking
People spend up to 90% of their life indoor, and the way we live and behave in our homes has substantial effects on our health and well-being. Particle contamination is suggested to have substantial negative effects on health, with candles and cooking emitting the largest amount of particles, thus being the largest contributors to indoor air pollution.
The overall aim of the present project is to contribute to increased understanding of the association between indoor particulate air pollution and health and well-being.
Study Overview
Status
Intervention / Treatment
Detailed Description
Introduction: People spend up to 90% of their life indoor, and the way we live and behave in our homes has substantial effects on our health and well-being. Particle contamination is suggested to have substantial negative effects on health, with candles and cooking emitting the largest amount of particles, thus being the largest contributors to indoor air pollution. Little is known about the potential adverse health effects of candles and cooking, and people with asthma may be more susceptible.
Aim: To investigate local and systemic effects of short-term exposure to lit candles and cooking among young asthmatics.
Design: In a randomised double-blinded cross-over study non-smoking asthmatics (18-25 years) were exposed for five hours at three different exposure conditions separated by 14 days; A) clean filtered air, B) lit candles and C) cooking emissions under controlled environmental conditions.
Measurements: TSI P-TRAK Ultrafine Particle Counter was used for particle counts. Health effects, including lung function (FEV1/FVC) and fraction of exhaled nitric oxide (FeNO) were evaluated in relation to local and systemic effects prior to, right after and 24 h. after exposure.
Analysis: Mixed methods approach taking both time and exposure into account.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Central Region Denmark
-
Aarhus, Central Region Denmark, Denmark, 8000
- Climate Chambers, Dept. Public Health, Aarhus University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 15-25
- Medically treated / physician diagnosed mild seasonal asthma
- Never smoker or ex-smoker ≥ 6 months
- Allergy > 1 common allergy
Exclusion Criteria:
- Any other disease that could influence the study parameters
- Conditions that prevent safe access to the climate chambers (such as claustrophobia)
- Perennial asthma
- Need for continuous medical treatment for asthma
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Clean Air
Just clean air - no exposure
|
Nothing but clean air
|
|
Experimental: Cooking
Four ovens were frying pork - one at a time.
When the first oven finished, the next oven started and so forth for approx.
7 hours.
|
Generating fine and ultrafine particles from frying pork in an oven
|
|
Experimental: Candles
10 lit candles were placed at a table.
Burning for approx.
7 hours with light ventilation.
|
Generating fine and ultrafine particles from lit candles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Particles in Exhaled Air (Surfactant Protein A & Albumin)
Time Frame: Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
PExA: Subjects performed repeated breath maneuvers allowing for airway closure and re-opening, and exhaled particles were optically counted and collected on a membrane using the (novel) PExA® instrument set-up.
|
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Lung Function (FEV1 & FVC)
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
Spirometry
|
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
|
Change in Fractional exhaled nitric oxide (FENO)
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
NIOX VERO system; Aerocrine AB, Sweden
|
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
|
Change in Blood samples
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
Cytokines (IL-8), DNA-damages
|
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
|
Change in nasal volume (using Acoustic rhinometry)
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
Is used to assess the nasal cross sectional area and volume.
The left and right nasal cavity were studied alternatively until three reproducible measurements were obtained.
The minimum cross sectional cavity area was calculated from the means of the measurements.
By integration of the area-distance curve, the sum of the volume 2 to 4 (vol2-4) from the nostril was determined on both sides.
|
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
|
Change in biomarkers in Saliva Sample
Time Frame: At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
An oral svap from Salivette was placed in the mouth of the participant to collect saliva by gently chewing the swab for one minute.
Afterwards the saturated swab was removed to the suspended insert and closed firmly with a lid.
Then the sample was transferred to a freezer and stored for -80 C until further analysis.
The sample will be analyzed for biomarkers (amylase, cortisol, substance P, lysozyme and secretory IgA.)
|
At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
|
|
Change in Subjective Symptoms
Time Frame: Every 30 minute during 5 hours of exposure
|
In the exposure chamber participants were asked to fill out a symptom questionnaire every 30 minute regarding their well-being and experienced symptoms in eyes, nose and throat.
The participants were asked to score their evaluation (rate the strength) of symptoms by placing a cross on a 130 mm open Visual Analogue Scale (VAS).
The intensity of any discomfort was registered as the length in mm from the left of the scale to the marker.
The scores were rated from 0 to 100% with highest number corresponding to highest discomfort.
Health effects were evaluated in relation to rated changes in symptoms.
|
Every 30 minute during 5 hours of exposure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karin R Laursen, MSc, Department of Public Health, Aarhus Universitet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 191100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Meyer Children's Hospital IRCCSRecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma ChildhoodItaly
-
Tel-Aviv Sourasky Medical CenterThe Dalia and Eli Hurvitz Foundation GrantNot yet recruitingAsthma Attack | Asthma AcuteIsrael
-
University of PittsburghNational Institute of Environmental Health Sciences (NIEHS)RecruitingAsthma Exacerbation | Childhood Asthma | Air Pollution, Risk Reduction Behaviors | Asthma ControlUnited States
-
Vanderbilt University Medical CenterWithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Columbia UniversityChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsNot yet recruitingAcute Asthma | Pediatric Asthma | Non-invasive Positive Pressure Ventilation | BiPAPUnited States
-
SingHealth PolyclinicsRecruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicSingapore
-
Johann Wolfgang Goethe University HospitalCompleted
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPersistent Asthma | Asthma (Diagnosis) | Moderate Asthma ExacerbationUnited States
Clinical Trials on Clean Air
-
Environmental Protection Agency (EPA)CompletedExposure to PollutionUnited States
-
Environmental Protection Agency (EPA)CompletedExposure to Environmental Pollution, Non-occupationalUnited States
-
Massachusetts General HospitalMbarara University of Science and TechnologyEnrolling by invitationPneumonia | Pollution; Exposure | Pediatric Respiratory Diseases | Lung Function Decreased | Chronic Respiratory Disease | Lungs; Developmental DisorderUganda
-
Environmental Protection Agency (EPA)CompletedExposure to Environmental Pollution, Non-occupationalUnited States
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS); Environmental...CompletedResponse of Viral Infection to WoodsmokeUnited States
-
Environmental Protection Agency (EPA)CompletedExposure to Environmental Pollution, Non-occupationalUnited States
-
Fraunhofer-Institute of Toxicology and Experimental...CompletedHealthy | Chronic Obstructive Pulmonary DiseaseGermany
-
University of AarhusThe Swedish Research Council for Environment, Agricultural Sciences and Spatial... and other collaboratorsCompletedDiscomfort Symptoms | Changed Lung FunctionDenmark
-
University of California, San FranciscoTobacco Related Disease Research ProgramSuspendedPollution; Exposure | Exposure to Pollution | Smoke InhalationUnited States